SNYRHIGH SIGNALFINANCIAL10-K

SNYR experienced a dramatic financial deterioration with net income swinging from $2.1M profit to -$12.3M loss while share count increased 31% suggesting significant dilution.

The company's transition from profitability to substantial losses, combined with a 31% increase in outstanding shares (from 8.6M to 11.3M), indicates potential financial distress and equity dilution. Despite improved operating cash flow and higher cash position, the overall financial trajectory shows severe operational challenges that require immediate investor attention.

Comparing 2026-04-01 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

SNYR's financial position deteriorated significantly with net income plummeting 681% from profit to substantial loss and operating income declining 246%. While the company improved its cash position (+281%) and reduced current liabilities by 52%, total assets declined 38% and stockholders' equity worsened to -$23.1M from already negative -$16.6M. The 31% increase in share count alongside massive losses suggests the company may be diluting shareholders to address liquidity needs, creating a concerning combination of operational deterioration and potential equity dilution.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-680.8%
$2.1M-$12.3M

Net income declined 680.8% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+281.2%
$688K$2.6M

Cash position surged 281.2% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-245.8%
$5.8M-$8.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Inventory
Balance Sheet
+117.7%
$1.7M$3.7M

Inventory surged 117.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Liabilities
Balance Sheet
-52.1%
$17.2M$8.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
+46.2%
-$4.8M-$2.6M

Operating cash flow surged 46.2% — exceptional cash generation, highest quality earnings signal.

Accounts Receivable
Balance Sheet
-39.8%
$5.3M$3.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-39.1%
-$16.6M-$23.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-37.8%
$16.3M$10.2M

Total assets contracted 37.8% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-37.6%
$16.1M$10.0M

Current assets declined 37.6% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-31
ADDED
Employer Identification No.) 770 Roosevelt Trail STE 8 #1016 N.
For the purposes of this disclosure, shares of common stock held by each executive officer, director and affiliate based on public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates.
This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of March 27, 2026, there were 11,483,926 shares of common stock, par value $0.00001 per share, of the registrant issued and 11,303,853 shares outstanding.
Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any U.S.
+7 more — sign up free →
REMOVED
The registrant s common stock began trading on The Nasdaq Stock Market on October 23, 2024.
As of March 27, 2025, there were 8,752,178 shares of common stock, par value $0.00001 per share, of the registrant issued and 8,572,105 shares outstanding.
Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any FDA-approved IND application) that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
Our products are sold through some of the nation s leading club, mass drug, and other retailers such as Costco, Amazon.com, Walmart, Walgreens, CVS, The Vitamin Shoppe, Target.com, H-E-B, Meijer, and Albertson s.
Additionally, we have expanded into Canada and the United Kingdom.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →